SCIEX发布4500MD系列用于体外诊断

2014年7月29日，AB SCIEX在芝加哥召开的美国临床化学学会年会(AACC)上推出支持诊断市场的Triple Quad 4500MD和QTRAP 4500MD液质系统，以上系统在SCIEX Diagnostics品牌下……

2014年7月29日，AB SCIEX在芝加哥召开的美国临床化学学会年会(AACC)上推出支持诊断市场的Triple Quad 4500MD和QTRAP 4500MD液质系统，以上系统在SCIEX Diagnostics品牌下。这两款系统预计于9月在美国及部分欧盟国家上市销售。除了4500MD系列外，AB SCIEX用于体外诊断器械的质谱还包括2013年推出的3200MD和IVD-MS分析系统，以及2014年8月在部分欧盟国家上市的一系列检测试剂盒，用于维生素D、免疫抑制剂和新生儿筛查检测等。

4500MD系列是一个灵活的LC/MS/MS平台，提供更高的性能，更高的灵敏度和更快的数据采集速度，使客户开发他们自己的应用方法，以验证那些需要更低的检出限和更高通量的方法。

AB SCIEX应用市场及临床研究副总裁Chris Radloff, 表示，“随着科学的认识逐步改善临床诊断测试，诊断客户倾向于使用快速，灵敏的仪器开发检测方法，从而是的常规测试更高效及成本更低。通过将灵活性，可靠性和准确性的质谱技术推向临床检测实验室，AB SCIEX能帮助客户提供高质量的诊断信息，以此影响临床医生对患者治疗的决定。”

SCIEX Diagnostics是专注于提供高品质的技术，服务和支持于临床诊断市场，它是AB SCIEX的一部分。

AB Sciex. (7/29/14). "Press Release: AB Sciex Announces the 4500MD Series for In vitro Diagnostic Use". Framingham, MA.

Industry leader increases mass spectrometry portfolio for clinical testing laboratories

AB SCIEX, a global leader in analytical technologies, today confirmed its commitment to support the diagnostic market with the unveiling of the Triple Quad™ 4500MD and QTRAP® 4500MD LC/MS/MS systems under its SCIEX Diagnostics brand. Expected to be available in the US and select EU countries in September, the 4500MD series joins the company"s growing family of in vitro diagnostic devices, including the 3200MD*, and IVD-MS™ Analyzer* systems launched in 2013, as well as a series of kits* for vitamin D, immunosuppressants and newborn screening testing to be available in August 2014 for use in certain European countries. 包括：Triple Quad™ 4500MD 和QTRAP® 4500MD LC/MS/MS 系统，9月将用于美国和几个欧盟国家。2013年，SCIEX曾推出3200MD临床质谱和一系列试剂盒用于体外诊断，包括维生素D、免疫抑制剂和新生儿筛查，从2014年8月开始用于特定的欧洲国家。

The new 4500MD series offers exceptional sensitivity and faster data acquisition over previous systems allowing clinical customers to obtain reliable results so physicians and patients have accurate answers quickly.

The 4500MD series is a flexible LC/MS/MS platform that offers enhanced performance, improved sensitivity and faster data acquisition, to enable customers developing their own applications to validate methods that require lower detection limits or higher throughput, with the peace of mind afforded by a regulatory compliant solution.

"As scientific understanding progressively evolves into improved clinical diagnostic testing, diagnostic customers who develop their own assays are turning to fast, sensitive instruments to perform routine tests with high efficiency and cost savings," said Chris Radloff, Vice President, Applied Markets and Clinical Research at AB SCIEX. "By bringing the power, flexibility, reliability, and accuracy of our mass spectrometry technology to clinical testing laboratories, AB SCIEX is enabling customers to deliver high quality diagnostic information to clinicians who make decisions affecting patient care."

SCIEX Diagnostics is focused on delivering high quality technology, service and support to the clinical diagnostics market and is part of AB SCIEX. Throughout the week at the 2014 AACC Annual Meeting, SCIEX Diagnostics will unveil its latest product at booth #3418. Follow AB SCIEX at AACC on Twitter with hashtag #ABSCIEXWORLD and #aacc2014.

About AB SCIEX

AB SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to find answers to the complex analytical challenges they face. The company"s global leadership and world-class service and support in the liquid chromatography-mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research. With over 25 years of proven innovation, AB SCIEX focuses on "Answers for Science. Knowledge for life," and excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis. For more information, please go to www.absciex.com.